IL215158A - History of imidazo [1,2– b] [4,3,1] thadiazole preserved in positions 2 and 5, a process for preparing them and their pharmaceutical preparations - Google Patents

History of imidazo [1,2– b] [4,3,1] thadiazole preserved in positions 2 and 5, a process for preparing them and their pharmaceutical preparations

Info

Publication number
IL215158A
IL215158A IL215158A IL21515811A IL215158A IL 215158 A IL215158 A IL 215158A IL 215158 A IL215158 A IL 215158A IL 21515811 A IL21515811 A IL 21515811A IL 215158 A IL215158 A IL 215158A
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
thiadiazole derivatives
disubstituted imidazo
imidazo
Prior art date
Application number
IL215158A
Other languages
English (en)
Hebrew (he)
Other versions
IL215158A0 (en
Original Assignee
Ct Nac Investigaciones Oncologicas Cnio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Nac Investigaciones Oncologicas Cnio filed Critical Ct Nac Investigaciones Oncologicas Cnio
Publication of IL215158A0 publication Critical patent/IL215158A0/en
Publication of IL215158A publication Critical patent/IL215158A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
IL215158A 2009-04-02 2011-09-15 History of imidazo [1,2– b] [4,3,1] thadiazole preserved in positions 2 and 5, a process for preparing them and their pharmaceutical preparations IL215158A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09380069 2009-04-02
PCT/GB2010/000674 WO2010112874A1 (en) 2009-04-02 2010-04-01 Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives

Publications (2)

Publication Number Publication Date
IL215158A0 IL215158A0 (en) 2011-12-29
IL215158A true IL215158A (en) 2015-07-30

Family

ID=40750794

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215158A IL215158A (en) 2009-04-02 2011-09-15 History of imidazo [1,2– b] [4,3,1] thadiazole preserved in positions 2 and 5, a process for preparing them and their pharmaceutical preparations

Country Status (23)

Country Link
US (1) US8815918B2 (enExample)
EP (1) EP2414369B1 (enExample)
JP (1) JP5615902B2 (enExample)
KR (1) KR101727264B1 (enExample)
CN (1) CN102388055B (enExample)
AU (1) AU2010231162B2 (enExample)
BR (1) BRPI1015367B8 (enExample)
CA (1) CA2756873C (enExample)
CY (1) CY1116880T1 (enExample)
DK (1) DK2414369T3 (enExample)
EA (1) EA022753B1 (enExample)
ES (1) ES2548571T3 (enExample)
HR (1) HRP20151126T1 (enExample)
HU (1) HUE027964T2 (enExample)
IL (1) IL215158A (enExample)
MX (1) MX2011010372A (enExample)
NZ (1) NZ595674A (enExample)
PL (1) PL2414369T3 (enExample)
PT (1) PT2414369E (enExample)
SG (1) SG175001A1 (enExample)
SI (1) SI2414369T1 (enExample)
WO (1) WO2010112874A1 (enExample)
ZA (1) ZA201107350B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
GB2480815A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
BR112012030621B1 (pt) 2010-06-01 2020-10-27 Summit (Oxford) Limited compostos para o tratamento de doença associada a clostridium difficile
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012047538A1 (en) 2010-10-06 2012-04-12 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
RU2598840C2 (ru) 2011-05-19 2016-09-27 Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii Новые соединения
KR101399484B1 (ko) 2011-07-14 2014-05-29 한국화학연구원 허피스바이러스 엑소뉴클리에이즈 활성 억제 물질을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
EP4006016A3 (en) 2014-08-29 2022-11-16 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EP3190888B1 (en) 2014-08-29 2020-06-10 CHDI Foundation, Inc. Probes for imaging huntingtin protein
CN118084937A (zh) 2018-08-21 2024-05-28 杏林制药株式会社 双环杂芳族环衍生物
SG11202102679QA (en) 2018-09-18 2021-04-29 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
PE20221318A1 (es) 2019-10-21 2022-09-08 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US20230355617A1 (en) * 2020-09-14 2023-11-09 The University Of Sussex Small molecule inhibitors of lemur tyrosine kinase 3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US4444770A (en) 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3208437A1 (de) 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
WO1997011075A1 (en) 1995-09-22 1997-03-27 Takeda Chemical Industries, Ltd. Triazole compounds, their production and use
EP1307462A2 (en) * 2000-08-09 2003-05-07 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
CA2364985A1 (en) 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
RU2005122484A (ru) 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US20060135571A1 (en) 2003-06-13 2006-06-22 Jaquith James B Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones
US20070112043A1 (en) 2003-06-13 2007-05-17 Jaquith James B Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP2308870A3 (en) 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7750000B2 (en) 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
BRPI0619252A2 (pt) 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
EP2012782A1 (en) 2006-04-13 2009-01-14 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
JP2009535386A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
WO2007136736A2 (en) 2006-05-19 2007-11-29 Codon Devices, Inc. Methods for nucleic acid sorting and synthesis
JP2009537621A (ja) 2006-05-22 2009-10-29 アストラゼネカ アクチボラグ インドール誘導体
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
US7732468B2 (en) 2006-11-15 2010-06-08 Cytovia, Inc. 3-aryl-6-aryl-[ 1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
CN101037445A (zh) 2007-04-14 2007-09-19 西北师范大学 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法
CN101754968A (zh) 2007-05-09 2010-06-23 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的取代的咪唑并哒嗪
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CA2688823A1 (en) 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
EP2180893B1 (en) * 2007-08-09 2014-11-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
DK2193133T3 (en) * 2007-09-27 2015-10-05 Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
US8389554B2 (en) 2008-07-29 2013-03-05 MERCK Patent Gesellschaft mit beschränkter Haftung Imidazothiadiazole derivatives

Also Published As

Publication number Publication date
EP2414369A1 (en) 2012-02-08
SG175001A1 (en) 2011-11-28
EA201101435A1 (ru) 2012-04-30
ZA201107350B (en) 2015-06-24
HUE027964T2 (en) 2016-11-28
WO2010112874A1 (en) 2010-10-07
ES2548571T3 (es) 2015-10-19
DK2414369T3 (en) 2015-09-21
HRP20151126T1 (hr) 2015-11-20
IL215158A0 (en) 2011-12-29
JP2012522759A (ja) 2012-09-27
CY1116880T1 (el) 2017-04-05
CN102388055A (zh) 2012-03-21
AU2010231162A1 (en) 2011-11-03
US8815918B2 (en) 2014-08-26
AU2010231162B2 (en) 2014-12-11
PL2414369T3 (pl) 2016-04-29
SI2414369T1 (sl) 2015-12-31
KR20120034607A (ko) 2012-04-12
BRPI1015367B1 (pt) 2021-05-11
KR101727264B1 (ko) 2017-04-14
CA2756873A1 (en) 2010-10-07
HK1166979A1 (zh) 2012-11-16
EA022753B1 (ru) 2016-02-29
CA2756873C (en) 2018-01-09
MX2011010372A (es) 2012-01-12
US20120094996A1 (en) 2012-04-19
EP2414369B1 (en) 2015-08-12
BRPI1015367A2 (pt) 2018-02-20
BRPI1015367B8 (pt) 2021-05-25
PT2414369E (pt) 2015-10-22
JP5615902B2 (ja) 2014-10-29
NZ595674A (en) 2012-12-21
CN102388055B (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
IL215158A (en) History of imidazo [1,2– b] [4,3,1] thadiazole preserved in positions 2 and 5, a process for preparing them and their pharmaceutical preparations
IL209258A (en) Derivatives of Pyrolopyridine, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses
IL213993A (en) History of 4,3,2,1-tetrahydropyrido [3,2-b] pyrazine-2-one and pharmaceutical preparations containing them
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
IL220544A (en) History of n - (h1 - indazole - 4 - ram) imidazo [2,1 - a] pyridine - 3 - carboxamide, processes for their preparation and pharmaceutical preparations containing them
IL219424A (en) Imidazo derivative [b – 1,2] pyridazine, combinations, distant preparations containing them and process for their preparation and use as pde10 inhibitors
IL215911A (en) 7-aryl-1,2,4-triazolo [3,4- a] derivatives, pharmaceutical preparations containing them and methods of preparation and uses thereof
IL215074A0 (en) Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
IL220571A (en) Compounds of 3 - (3-phenyl-imidazo [5,4- b] pyridinyl) -2-conjugated aminopyridine and pharmaceutical preparations containing them
IL196280A0 (en) Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them
IL216609A0 (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
IL192826A0 (en) Thiazole derivatives, their preparation and pharmaceutical compositions containing them
SI2107055T1 (sl) Derivati diosmetina, postopek za njihovo pripravo in njihovi farmacevtski sestavki
IL218539A (en) Annotated 4,1-Androsteadian-3-Oxo-9,6-Dihlo-16-Isoxazolidine-17-Noble N-Converted
IL216692A0 (en) Pyrazole oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
IL212942A (en) History of Rifamycin, Methods of Preparation, Pharmaceutical Preparations Containing Them and Their Uses
ZA201100428B (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
IL217293A (en) Annotations of 9,8,7,6-tetrahydropyrimido {{a-2,1 pyramidine-4-one)
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
IL205710A (en) History of Spiro [Pipyridine-Benzopyran] Pharmaceuticals Containing Them, Methods of Preparing and Using Their @
IL217294A (en) History 3,2 - Dihydro - 1h - Imidazo [1, 2 - a] - Pyrimidin - 5 - On, process for their preparation, pharmaceutical preparations containing them and their use in the preparation of medicines
IL213590A0 (en) Oxadiazole fused heterocyclic derivatives, their preparation and pharmaceutical compositions containing them
IL214907A (en) Derivatives of benzothiazines, methods for their preparation and medicinal compounds containing them
HUP0700395A2 (en) Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed